Gliatech and Chugai sign licensing agreement:
This article was originally published in Clinica
Executive Summary
Chugai Pharmaceutical is to market Gliatech's Adcon-L and Adcon-T/N anti-adhesion barrier gels in Japan under an exclusive licence agreement announced by the two companies on January 13th. Chugai will fund and conduct all clinical trials and regulatory filings required to obtain marketing approval for the products in Japan. Adcon-L and Adcon-T/N are the first in a line of products being developed by Gliatech (US) for the inhibition of post-surgical scarring and adhesions. Both products are already on the market in Europe, and are in clinical trials in the US.
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.